SubHero Banner

Keytruda® (pembrolizumab) – Expanded indication

October 16, 2023 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

Download PDF